Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin

Clinical Cancer Research

Volumn 17, Issue 20, 2011, Pages 6574-6581

  Tarhini, Ahmad A ^a   Frankel, Paul ^b   Margolin, Kim A ^c   Christensen, Scott ^d   Ruel, Christopher ^b   Shipe Spotloe, Janice ^a   Gandara, David R ^d   Chen, Alice ^e   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BONE NECROSIS; BRAIN ISCHEMIA; CANCER STAGING; CLINICAL ARTICLE; CONFUSION; COUGHING; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INOPERABLE CANCER; KIDNEY FAILURE; LYMPHOCYTOPENIA; MALE; MELANOMA; MEMORY DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPHTHALMOPLEGIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; SURVIVAL RATE; THORAX PAIN; THROMBOCYTOPENIA; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS; UVEAL NEOPLASMS;

EID: 80054097652     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1463     Document Type: Article

References (41)

1. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49. (Pubitemid 351656458)
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
3. Mehnert J, McCarthy M, Aziz S, Sznol M, Flaherty K, Camp R, et al. VEGF, VEGFR1, and VEGFR2 expression in melanoma.J Clin Oncol 2007;25:18s, (suppl; abstr 8520).
4. Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D, et al. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 2003;89:426-30. (Pubitemid 37026421)
5. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80:98-106. (Pubitemid 27270925)
6. Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, et al. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 2010;41: 375-84.
7. Soubrane C, Mouawad R, Rixe O, Spano JP, Gatineau M, Khayat D. Changes in circulating VEGF-A levels related to clinical response during biochemotherapy in metastatic malignant melanoma.J Clin Oncol 2004;22:14s, (suppl, abstr 7531).
8. Soubrane C, Mouawad R, Sultan V, Spano J, Khayat D, Rixe O. Soluble VEGF-A and lymphangiogenesis in metastatic malignant melanoma patients. J Clin Oncol 2006;24:18s, (suppl, abstr 8049).
9. Mouawad R, Meric J, Spano J, Auclerc G, Rixe O, Khayat D, et al. Relationship of soluble VEGF-C and VEGF-D with clinicopathological parameters in metastatic malignant melanoma patients treated by biochemotherapy. J Clin Oncol 2005;23:16s, (suppl, abstr 7540).
10. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 2006;16:405-11. (Pubitemid 44511220)
11. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103. (Pubitemid 26338628)
12. Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003;101:4878-86.
13. Cancer Therapy Evaluation Program. Aflibercept (AVE0005) investigator's brochure. 9th ed. Bethesda, MD: National Cancer Institute, NIH; 2009.
14. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010;28:207-14.
15. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66. (Pubitemid 30036349)
16. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-25. (Pubitemid 41095046)
17. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 2003;22:abstr 2847.
18. Tu YT, Tao J, Liu YQ, Li Y, Huang CZ, Zhang XB, et al. Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis. Clin Exp Dermatol 2006;31:413-8.
19. Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol 2007;34:555-65. (Pubitemid 350236307)
20. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-25. (Pubitemid 32176299)
21. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001;19:265-72. (Pubitemid 32063505)
22. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34. (Pubitemid 351264344)
23. Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009;27:2645-52.
24. Perez DG,Suman VJ, Fitch TR, Amatruda T III, Morton RF, Jilani SZ,et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009;115:119-27.
25. O'Day S, Kim K, Sosman J. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Eur J Cancer Suppl 2009;7:abstr 13.
26. Dummer R, Michielin O, Seifert B. First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): a multicenter phase II trial (ASKK 50/07). J Clin Oncol 2010;28:15s.
27. Fruehauf JP, Trapp V. Reactive oxygen species: an Achilles' heel of melanoma? Expert Rev Anticancer Ther 2008;8:1751-7.
28. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
29. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24:1363-9. (Pubitemid 46621999)
30. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35. (Pubitemid 46630490)
31. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
32. Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol 2009;27:6152-9.
33. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807-15.
34. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-65. (Pubitemid 36350732)
35. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274:H1054-8.
36. Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol 2005;90:315-26. (Pubitemid 40685844)
37. Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med 2004;255:538-61. (Pubitemid 38534868)
38. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010;28:949-54.
39. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8.
40. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-30.
41. Wick A, Schafer N, Dorner N, Schemmer D, Platten M, Bendszus M, et al. Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. J Neurooncol 2010;97:157-8.